TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10375203
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BAP levels and percent BAP change at 6 months
Study: 6130292
Drug: Naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone treatment (oral and intravenous)
Study: 6130292
Drug: Control (large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (large daily doses of laxatives and additional suppositories and enemas)
Study: 3515468
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g or 2 g once daily for 7-12 days)
Study: 25560155
Drug: Isotonic fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic fluid (0.9% NaCl solution in 5% dextrose)
Study: 21197498
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading (111 implants, 45 patients)
Study: 21197498
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading (111 implants, 51 patients)
Study: 21197498
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement with immediate function (group 1)
Study: 21197498
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement with immediate function (group 2)
Study: 21197498
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement with delayed function (group 3)
Study: 21197498
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement with delayed function (group 4)
Study: 21197498
Drug: Immediate function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate function implants
Study: 18386572
Drug: Ningzhi Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningzhi Capsule (NZC) 5 tablets, 3 times a day for 6 months
Study: 10092691
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg, 2 mg/puff, two puffs three times daily)
Study: 10092691
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two puffs three times daily)
Study: 1757042
Drug: 2% MK-507
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% MK-507 (both formulations)
Study: 6850464
Drug: BCG administered
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG administered orally in patients with resectable colon cancer
Study: 6850464
Drug: BCG administered
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG administered intraperitoneally along with 5-fluorouracil for gastrointestinal cancer
Study: 29621811
Drug: Injected Vitamin
Normalized name: vitamin A Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected Vitamin D (300,000 units in 1 cc)
Study: 29621811
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo, 1 cc)
Study: 24585722
Drug: Bevacizumab-pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab-pemetrexed (500 mg/m2)
Study: 31780570
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 mg/kg)
Study: 17522988
Drug: Methylphenidate, gradually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate, gradually increasing dosage over two weeks, followed by a similar two-week period of gradually diminishing dosage.
Study: 12167115
Drug: Omeprazole (OMP)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (OMP) 20 mg once daily
Study: 12167115
Drug: Famotidine (FAM)
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine (FAM) 20 mg twice daily
Study: 8913711
Drug: Ondansetron (O)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (O) 16 mg 3 times/day
Study: 1905438
Drug: Dextrose 70%
Normalized name: DEXTROSE 70% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 70% injection (D70W) plus 15% amino acids for PN, 25-mL piggybacks, selected drugs added to the PN solution
Study: 1905438
Drug: D70W plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: D70W plus 10% amino acids, 50- or 100-mL piggybacks
Study: 6393976
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg ASA/d
Study: 6393976
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ASA/d
Study: 6393976
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ASA/d
Study: 6393976
Drug: No ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ASA administration (control group)
Study: 29204869
Drug: Valerate estradiol
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valerate estradiol 2 mg daily + dihydrogesterone 10 mg daily during luteal phase for 3 months before IVF
Study: 16936304
Drug: No pre-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre-treatment
Study: 27528065
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of plasminogen activator inhibitor-1 levels in fasting serum
Study: 15763055
Drug: Toubiao Qingfei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toubiao Qingfei Decoction (TBQFD) + Western medicines
Study: 18416072
Drug: Western medicines
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicines
Study: 10442359
Drug: uracil/tegafur plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: uracil/tegafur plus oral calcium folinate (UFT)
Study: 10442359
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) plus oral calcium folinate
Study: 11015032
Drug: Promethazine 50
Normalized name: promethazine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 50 mg
Study: 31376501
Drug: Parent-Child Interaction
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-Child Interaction Therapy with Emotion Development module (PCIT-ED)
Study: 20183659
Drug: Standard Parent-Child
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Parent-Child Interaction Therapy (PCIT)
Study: 25987078
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human endostatin (Endostar) 7.5 mg/m2, administered on postoperative day 89, 34 h/time, daily, for 14 weeks, total of 4 cycles
Study: 25987078
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received postoperative complementary chemotherapy containing two-agent platinum protocol
Study: 12024434
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C meningococcal conjugate vaccine
Study: 11402115
Drug: L-dopa (300/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (300/75 mg/d)
Study: 11402115
Drug: Pramipexole (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (1.5 mg/d)
Study: 9431265
Drug: Electrical Nerve
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Nerve Stimulation (ENS) therapy
Study: 9431265
Drug: Electrical Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Muscle Stimulation (EMS) therapy
Study: 3900847
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (control group)
Study: 30645864
Drug: Meat-containing canned
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat-containing canned food for enteral nutrition (240 ml, 2 portions daily for 14 days)
Study: 19595605
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (conventional haemostatic fleece)
Study: 17621464
Drug: Sequential pegylated
Normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pegylated interferon‐α2a plus delayed‐initiation tenofovir
Study: 20811582
Drug: Opioid receptor
Normalized name: Opioid receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid receptor antagonist naloxone
Study: 18267008
Drug: Conventional wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional wound therapy
Study: 16835758
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated Oka strain varicella vaccine (Varilrix, GlaxoSmithKline Biologicals)
Study: 12590879
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of hyaluronans
Study: 10773631
Drug: Chlorhexidine varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine varnish (CV, Cervitec) containing 1% chlorhexidine and 1% thymol, treated every 3rd month for 3 years (12 treatments total)
Study: 3436485
Drug: Ferritin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin (80 mg Fe3+)
Study: 26875428
Drug: Heart rate-guided
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate-guided beta-blocker titration
Study: 26875428
Drug: Beta-blocker uptitration
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker uptitration
Study: 23541564
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus everolimus (5mg p.o. daily, after a step-wise dose-escalation starting from 2.5mg bid) for 12 weeks before surgery
Study: 23541564
Drug: Paclitaxel alone
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel alone (80 mg/m(2) weekly for 12 weeks)
Study: 18091017
Drug: 6.4% carbohydrate-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% carbohydrate-electrolyte (CHO-E) solution
Study: 1461553
Drug: nimesulide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide (200 mg/day)
Study: 27499311
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (40 mg/day women, 160 mg/day men) and high energy oral nutritional supplement (2108-2416 kJ/day)
Study: 27499311
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication and low energy (142-191 kJ/day) 'placebo' oral nutritional supplementation
Study: 27499311
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate and nutritional supplementation
Study: 22434018
Drug: Hearing augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hearing augmentation device
Study: 22434018
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hearing augmentation)
Study: 20616774
Drug: Arginine-containing nutritional
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine-containing nutritional supplement (9 g per day until full PU healing)
Study: 18534138
Drug: Insulin-blood cardioplegia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-blood cardioplegia (insulin and glucose added)
Study: 18534138
Drug: Insulin-blood cardioplegia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-blood cardioplegia
Study: 6449783
Drug: IK-6 (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: IK-6 (combination of fenoterol and ipratropium bromide)
Study: 31434537
Drug: Hand-Arm Bimanual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand-Arm Bimanual Intensive Therapy (H-HABIT)
Study: 26163644
Drug: Arm I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm I: Irradiation of the whole pelvis to a dose of 50 Gy in 27 fractions, weekly cisplatin 40 mg/m2, HDR-ICBT after one week of completion of EBRT (7 Gy to point A for three insertions at one week intervals)
Study: 26163644
Drug: Arm II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm II: Irradiation of the whole pelvis to a dose of 50 Gy in 27 fractions, cisplatin 20 mg/m2/day from D1‐5 and D24‐28, HDR-ICBT after 40Gy (7 Gy to point A for three insertions on days 23, 30, 37)
Study: 24261438
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of paracetamol, chlorphenamine and phenylephrine (5 capsules per day for 48 to 72 hours)
Study: 24261438
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 capsules per day for 48 to 72 hours)
Study: 17449194
Drug: Low pretreatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pretreatment EBV DNA (<1,500 copies/mL) and undetectable posttreatment EBV DNA (pre-L/post-U)
Study: 17449194
Drug: High pretreatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High pretreatment EBV DNA (>=1,500 copies/mL) and undetectable posttreatment EBV DNA (pre-H/post-U)
Study: 17449194
Drug: Low or
Normalized name: Milkflow oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low or high pretreatment EBV DNA and detectable posttreatment EBV DNA (pre-L or H/post-D)
Study: 10224730
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CB)
Study: 8063980
Drug: Brief psychodynamic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychodynamic therapy (PD)
Study: 31782814
Drug: Budesonide (BD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (BD; 256 μg) for 2 weeks
Study: 31782814
Drug: Budesonide (BD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (BD; 256 μg) plus Montelukast (MNT; 10 mg) for 2 weeks
Study: 30291868
Drug: MRI-PDFF (MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-PDFF (MR imaging estimated proton density fat fraction) after 24 weeks of treatment with selonsertib
Study: 25052217
Drug: Intravenous piracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous piracetam (2000 mg)
Study: 21700922
Drug: Prism adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism adaptation (PA) therapy - repetitive pointing with prism glasses inducing rightward optical shift, twice daily, 5 days per week, for 2 weeks.
Study: 15936046
Drug: Small sized
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small sized compound letters (where global shape was more salient)
Study: 12972982
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg TRH
Study: 3958225
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of triazolam 0.5 mg
Study: 3958225
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of triazolam 0.5 mg
Study: 26670129
Drug: Elastic compression
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastic compression stocking (ECS) therapy for 2 years
Study: 26670129
Drug: Elastic compression
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastic compression stocking (ECS) therapy with ability to put on independently
Study: 26670129
Drug: ECS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECS therapy
Study: 20113765
Drug: Once-weekly supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly supervised pulmonary rehabilitation (n=15)
Study: 20113765
Drug: Twice-weekly supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly supervised pulmonary rehabilitation (n=15)
Study: 8550853
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) 1,000 mg/m2 intravenously over 24 h
Study: 6122111
Drug: Oral diazoxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazoxide
Study: 6122111
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (diuretic + beta‐adrenoceptor blocker + hydralazine + prazosin)
Study: 23803871
Drug: Ketamine (0.54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.54 mg/kg within 30 min)
Study: 12510415
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 mg twice a day
Study: 9856708
Drug: Systemic lidocaine
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic lidocaine (2 mg/kg bolus followed by 2 mg x kg(‐1) x h(‐1) infusion for 50 min)
Study: 9856708
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional anesthesia with lidocaine (40 ml, 0.05%)
Study: 9856708
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (systemic and regional lidocaine)
Study: 553663
Drug: Chlorpheniramine inhalation
Normalized name: chlorpheniramine / phenylephrine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine inhalation
Study: 25044531
Drug: SRP+AZM (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP+AZM (500 mg oral delivery × 3 days)
Study: 23083066
Drug: CHMP 3×2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHMP 3×2 tablets per day
Study: 23083066
Drug: CHMP 2×2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHMP 2×2 tablets per day
Study: 23083066
Drug: Placebo (3×2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3×2 tablets per day)
Study: 20215608
Drug: Inactivated trivalent
Normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated trivalent influenza vaccine
Study: 8277200
Drug: Cold-adapted vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted vaccine
Study: 29069415
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccines (PCVs)
Study: 26565716
Drug: Dapivirine (0.05%)
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine (0.05%) gel
Study: 25948671
Drug: Lowest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest quartile of SFA intake (<17.39 g/d)
Study: 23994919
Drug: Reosorbilact (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reosorbilact (200-400 ml intravenously for 20 days)
Study: 12804135
Drug: Plasmid DNA
Normalized name: Immunotherapeutic vaccine consisting of pAc/emm55, a plasmid DNA (pDNA), which codes for a modified immunogenic, streptococcal Emm55 protein, complexed with in vivo-jetPEI¬Æ polymer-based reagent linear polyethylenimine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmid DNA encoding gp100 administered intramuscularly (n = 12)
Study: 405412
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (N)
Study: 30345658
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messages consisting of multiple-choice questions with links to online material
Study: 21227600
Drug: Δ⁹‐THC (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ⁹‐THC (30 mg)
Study: 3017596
Drug: Nabilone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (1 mg)
Study: 11499328
Drug: Tretinoin 0.1%
Normalized name: TRETINOIN 0.1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.1% gel microsponge
Study: 9990419
Drug: Tretinoin 0.025%
Normalized name: TRETINOIN 0.025% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.025% gel
Study: 11499328
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel (once-daily)
Study: 11499328
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel (alternate-day)
Study: 2865009
Drug: Ciclopirox olamine
Normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox olamine cream 1%
Study: 27989639
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment (ET)
Study: 21872140
Drug: Management guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management guided by daily noninvasive estimated LVEDP monitoring (Group I, open)
Study: 7533030
Drug: Doxazosin Mesylate
Normalized name: Doxazosin Mesylate
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxazosin Mesylate (1 to 2 mg and from 2 to 4 mg over 45 days)
Study: 30044899
Drug: Cyclosporine 100
Normalized name: cyclosporine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 100 mg twice daily for 5 days with Amenamevir 400 mg and 1200 mg single doses
Study: 26850023
Drug: Financial incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial incentives for adherence to anti-psychotic medication
Study: 22947249
Drug: Low-dose b240
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose b240 (2 × 10^9 cells)
Study: 22947249
Drug: High-dose b240
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose b240 (2 × 10^10 cells)
Study: 22947249
Drug: b240 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: b240 (both doses)
Study: 10851674
Drug: Combined surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined surgery and radiation therapy
Study: 3924081
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (Transiderm‐Nitro 5)